Annual Report 2024
Annual Report 2024
Tim Van Hauwermeiren
Chief Executive Officer
Peter Verhaeghe
Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer
Peter Verhaeghe
Chairman of the Board
Message to Our Shareholders
As we reflect on 2024, we are filled with pride and gratitude for the remarkable progress and achievements that have defined this year for argenx. We are more committed than ever to transforming the treatment of severe autoimmune diseases and the milestones we have reached are a testament to the dedication and resilience of our entire team.
This year, we made significant steps in expanding the reach and impact of VYVGART® (efgartigimod alfa-fcab), our first-in-class antibody fragment targeting FcRn. With approvals for both intravenous and subcutaneous formulations in multiple indications, including gMG, primary immune thrombocytopenia (ITP), and CIDP, we are now able to offer life-changing treatments to more than 10,000 patients globally.
Read the Shareholder LetterWe hear you
Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that "together we are better". As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.
Read our patient stories
Financial highlights
Explore 2024 in Brief2025 Outlook
In 2024, we established our ‘Vision 2030’ outlining our long-term commitment to transform the treatment of severe autoimmune disease with VYVGART, empasiprubart and our expanding pipeline of antibody-based therapeutics. With our eyes set on 2030, we are targeting the treatment of 50,000 patients globally, securing 10 labeled indications across all approved medicines, and advancing five pipeline candidates into Phase 3 development.
Read the 2025 Outlook